Boehringer Ingelheim Caps Inhaler Costs at $35 Amid Scrutiny

The pharmaceutical company's decision comes after pressure from Democratic senators and aims to make healthcare more affordable for patients.

Boehringer Ingelheim announces a cap on out-of-pocket costs for all its inhaler products at $35 a month, starting June 1.
The decision aims to support patients with employer-sponsored insurance, and those who are underinsured and uninsured.
The move follows scrutiny from Democratic senators and is part of a broader effort to make healthcare more affordable.
Sen. Bernie Sanders praises the initiative, urging other companies to follow suit.
The initiative is compared to similar actions taken by insulin manufacturers last year.